#Sustiva

Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston

Such generic drugs could save nations huge sums in the coming years.

A major randomized, double-blind study pitted Livalo (pitavastatin) against Pravachol (pravastatin).

Harvoni and the combination of Sovaldi and daclatasvir were the least likely to cause a severe reaction with the HIV regimens of a cohort of H...

People who coinfected with HIV and hepatitis C looking to take the HCV drug Olysio may need to change HIV medications to avoid drug-drug inte...

Harvoni yielded a 96 percent cure rate among people with genotype 1 of hepatitis C, as well as a small number of those with genotype 4.

Twelve weeks of Gilead Sciences newly approved Harvoni cured nearly all people with genotype 1 of hepatitis C who were coinfected with HIV in...

Sovaldi (sofosbuvir) and ribavirin cured between 84 percent and 91 percent of people coinfected with HIV and genotypes 1 through 4 of hepatiti...

At the recent Conference on Retroviruses and Opportunistic Infections researchers reveled in promising new data on hepatitis C therapies.

Interim results from a trial of the hep C drug faldaprevir, given to people coinfected with hep C and HIV, have shown an 80 percent early succ...

Long-term studies have found that Isentress is both safe and effective in suppressing HIV among adult patients coinfected with hepatitis B, C...

Important preliminary recommendations involving the use of hepatitis C protease inhibitors among people living with HIV are provided by U.S. D...

The hepatitis C protease inhibitor Victrelis (boceprevir) has some significant drug-drug interactions with common Norvir (ritonavir)-boosted p...

The odds of curing hep C are now better than ever.

Vertex Pharmaceuticals? hepatitis C virus (HCV) protease inhibitor telaprevir interacts to varying degrees with commonly used HIV antiretrovir...

The U.S. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents has come nearly full circle...